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Abstract. The effects of HIV co-infection and multi-drug resistant tuberculosis (MDRTB) on tuberculosis prognosis
are poorly defined. Therefore, we studied infectiousness and mortality of 287 tuberculosis patients treated with standard,
directly observed, short-course therapy in the Peruvian community. During 6–17 months of treatment, 49 (18%) of
patients died, of whom 48 (98%) had AIDS and 28 (57%) had MDRTB; 17/31 (55%) of MDRTB-patients with AIDS
died within 2 months of diagnosis, before traditional susceptibility testing would have identified their MDRTB. Most
non-MDRTB became smear- and culture-negative within 6 weeks of therapy, whereas most MDRTB remained sputum-
culture-positive until death or treatment completion. HIV-negative patients with non-MDRTB had good outcomes.
However, MDRTB was associated with prolonged infectiousness and HIV co-infection with early mortality, indicating
a need for greater access to anti-retroviral therapy. Furthermore, early and rapid tuberculosis drug-susceptibility testing
and infection control are required so that MDRTB can be appropriately treated early enough to reduce mortality and
transmission.
INTRODUCTION
Tuberculosis kills 1.7 million people each year.1 Modern
treatment regimens are generally associated with a good
prognosis,2 but HIV co-infection3 and multi-drug resistant
tuberculosis (MDRTB)4 have poorly defined effects upon
treatment outcome5 and infectiousness.6 Peru has a model
tuberculosis control program2 and an HIV prevalence < 0.5%
but is one of the 30 highest tuberculosis-burden countries,
with a tuberculosis incidence of 188/100,000 in the year 2003.2
MDRTB rates have recently exceeded 3% of all new cases
and 9% of infectious sputum microscopy-positive patients,
making Peru one of the eight highest MDRTB-burdened
countries.4,7,8 As in most resource-poor settings, tuberculosis
drug-susceptibility testing is restricted to high-risk groups,
and facilities for respiratory isolation are sparse.7 In this set-
ting, a prospective cohort study was performed to study the
effects of HIV and MDRTB on tuberculosis infectiousness
and mortality during tuberculosis therapy.
PATIENTS
All adults who were diagnosed consecutively by the Peru-
vian National Tuberculosis Control Program as having labo-
ratory-proven pulmonary tuberculosis were invited to join the
study over a 17-month period at two diagnostic centers. In-
formed written consent was given by 287 patients (Table 1):
223 (78%) patients were diagnosed at the Maria Auxiliadora
general hospital outpatient clinic, where TB was diagnosed
principally by sputum microscopy; and 64 (22%) patients
were diagnosed concurrently at the infectious diseases unit at
Dos de Mayo Hospital, the principal referral center for
people with HIV infection in Lima, which serves an area
including that of Maria Auxiliadora Hospital. National policy
recommends a 12-month course of isoniazid preventive
therapy for all HIV-seropositive people, and we considered
this to have been taken if  3 months had been completed.
Extrapulmonary tuberculosis was not studied. This project
had national and international ethical approval, including
A.B. Prisma, Peru, and Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD.
METHODS
Investigations. For initial tuberculosis diagnosis, the Minis-
try of Health clinical laboratory performed Ziehl-Neelsen
sputum microscopy and, for patients known to be HIV-
positive, sputum culture on modified Ogawa medium with
drug-susceptibility testing by the proportions method.
For this study, two additional sputum samples were sub-
jected to auramine microscopy9,10 and culture with both the
7H9 broth microscopic observation drug-susceptibility
(MODS) assay11,12 and Lowenstein-Jensen slopes10 in the
university research laboratory, and these results, that con-
firmed tuberculosis in all cases, were used for our analysis.
MDRTB was defined as resistance to at least isoniazid (0.4
mg/mL) and rifampicin (1.0 mg/mL) in MODS and the mi-
croplate colorimetric assay.13 Chest radiographs were not
studied.
At the general hospital, ELISA HIV antibody testing was
done after counseling for 176 (79%) patients and was positive
in 8 (5%) cases. The remaining 47 (21%) patients at the gen-
eral hospital stated that they had no behavioral risk factors
for HIV infection and did not have HIV tests. Because HIV
is relatively uncommon in Peru, infecting 0.5% of the popu-
lation and 1.7% of tuberculosis patients,7 these 47 patients
were considered HIV-seronegative for all analyses. All 64
patients at the infectious diseases unit were HIV-seropositive
by ELISA with confirmatory Western blot assay, but HIV
clinical staging data, CD4 counts, and viral load measure-
ments were not available for this study.
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Treatment. All patients received the standard Peruvian
treatment regimen with direct observation of tablet consump-
tion at local health posts.2 Treatment was therefore unaf-
fected by recruitment center. This study was not involved in
patient care or treatment, but all laboratory results were rap-
idly communicated to patients and their clinicians, including
the results of first-line drug susceptibilities. In line with Pe-
ruvian national policy, all patients received a complete trial of
first-line tuberculosis therapy. Most patients were treated
with 2 months of isoniazid (H), rifampicin (R), pyrazinamide
(Z), and ethambutol (E) for 6 days/week, followed by 4
months of H and R for 2 days/week (2HRZE6/4HR2). Pa-
tients known to be co-infected with HIV and tuberculosis
received 2HRZE6/7HR2. If tuberculosis had been treated
previously, then streptomycin (S) was added: 1SHRZE6/
2HRZE6/5HRE2. Only 12 patients received second-line drugs
for a short term, due to cost and availability and these were
administered in addition to the standard treatment regimen:
ciprofloxacin alone in 5 cases, with ethionamide ± kanamycin
and amoxicillin-clavulanate in 4 cases, and other regimens in
3 cases.
Follow-up. Recruitment took place from February 1999 to
July 2000, and follow-up continued for each patient until
completion of therapy (April 2001). After diagnosis and re-
cruitment to the study, medical care and treatment were iden-
tical for all patients in the same community DOTS program,
irrespective of the place of recruitment. Tuberculosis treat-
ment adherence and survival at least to treatment completion
were determined for 224 (78%) participants, and 217/224
(97%) completed tuberculosis treatment. Survival analysis
was based upon the interval from tuberculosis treatment ini-
tiation until the first occurring date of: treatment completion,
death; default from therapy; loss to follow-up; or end of study.
Infectiousness during follow-up was analyzed for both tu-
berculosis microscopy and culture as the time from initiation
of therapy until the mid-point between the last positive result
and the first of 2 consecutive negative sputum specimens, or
the last positive result if there was no conversion.14 All par-
ticipants provided diagnostic sputum samples, and we col-
lected additional samples 2 weeks later from 108 (38%); after
1 month of treatment from 259 (90%); after 2 months treat-
ment from 249 (86%); after 4 months treatment from 229
(78%); and later in treatment from 166 (54%).
Statistical analysis. Person-years of observation were calcu-
lated by recording the total number of surveillance days for
each participant. For individuals lost to follow-up, person-
time denominator data were censored at the time of the last
visit. Continuous variables were compared using the Stu-
dent’s t test or the Mann-Whitney U test. Categorical vari-
ables were compared using the 2 test or Fisher’s exact test.
Kaplan-Meier survival analysis was performed to evaluate
time to conversion and time to death, and Cox proportional
hazards regression analysis was performed to evaluate risk
factors associated with conversion and mortality. The magni-
tude of associations of potential risk factors was expressed as
hazard ratios (HR). Risk factors with P < 0.15 in univariate
analyses were included in multiple regression analysis. All P
values were two-sided. All statistical analyses were carried
out using SPSS, version 13.0 (SPSS Corp., Chicago, IL).
RESULTS
Survival. The survival curves shown in Figure 1 demon-
strate the effects of HIV and MDRTB on mortality: 49 (17%)
of patients who were followed-up, died; 48 (67%) of 72 HIV-
infected patients died compared with 1 (0.5%) of 215 HIV-
negative patients (P < 0.0001), who died of hepatitis. MDRTB
was diagnosed in 18% of all patients and in 71% of the pa-
tients who died.
The major predictor of mortality was HIV infection and
there were also significant associations with: MDRTB; previ-
ous tuberculosis treatment; and lack of known exposure to a
tuberculosis case at home or work (implying a greater prob-
ability of tuberculosis transmission outside of the home, in-
cluding nosocomial transmission) (Table 2). HIV and
MDRTB co-infection caused 55% mortality 2 months after
diagnosis, and only 16% survived to complete 9 months of
therapy. Considering each center separately, 45/64 (70%) of
the patients diagnosed at the infectious diseases unit died
during follow-up. In contrast, 4/223 (1.8%) of patients re-
cruited at the general clinic died, 3 of whom were HIV-
positive. However, in multiple regression analysis, the site of
patient recruitment was not independently associated with
mortality. This difference in mortality between hospitals was
explained by HIV and MDR prevalence: prognosis was simi-
larly poor for HIV-positive tuberculosis patients recruited
from either hospital (Table 2).
Infectiousness. Durations of sputum smear and culture
positivity are shown in Figure 2. Most patients whose sputum
initially grew MDRTB remained smear- and culture-positive
TABLE 1
Clinical characteristics of the study population at diagnosis according to clinic
Feature
All participants
(n  287)
General clinic
(n  223)
ID unit
(n  64)
P value
comparing hospitals
HIV seropositivity 72 (25) 8 (5) 64 (100) < 0.001
MDRTB at time of diagnosis 51 (18) 21 (9) 30 (47) < 0.001
Outpatient at time of diagnosis 257 (90) 223 (100) 34 (53) < 0.001
Sputum smear positivity 274 (96) 223 (100) 51 (80) < 0.001
Previous TB treatment 60 (21) 37 (17) 23 (36) 0.001
Known TB exposure at home/work 103 (36) 83 (37) 20 (31) ns
Previous TB preventive therapy 18 (6) 3 (1) 15 (23) < 0.001
Hospitalization in last 2 years 45 (16) 23 (10) 22 (34) < 0.001
Male sex 182 (63) 130 (58) 52 (81) 0.001
BCG scar(s) 257 (90) 199 (89) 58 (91) ns
Age in years: mean (SD) 29 (11) 28 (11) 31 (8) ns
Note: The number (percentage) of patients with relevant clinical characteristics are shown for the whole study population and divided according to the hospital at which tuberculosis was
diagnosed. Tuberculosis was treated within the same community health posts.
Abbreviations: HIV, human immunodeficiency virus; MDRTB, multi-drug resistant tuberculosis; TB, tuberculosis; BCG, Bacillus Calmette-Guerin; SD, standard deviation; ID, infectious
diseases; ns, no significant difference.
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throughout follow-up. In contrast, most non-MDRTB be-
came smear- and culture-negative in the first 6 weeks of
therapy. Cox regression analysis revealed MDRTB to be the
main risk factor for prolonged positive sputum smear (HR 
3.6, 95% CI  1.9–6.6, P < 0.001) and culture (HR  3.8,
95% CI  2.1–6.9, P < 0.0001). As patient age increased, so
did the duration of positive sputum smear (P  0.04) and
culture (P = 0.05). Although HIV co-infection had borderline
associations with prolonged positive sputum smear and cul-
ture in univariate analysis, neither approached statistical sig-
nificance in multiple regression analysis that included the ef-
fect of MDRTB. Mortality was also associated with pro-
longed positive sputum smear (HR  14, 95% CI  6.7–27,
P < 0.001) and culture (HR 8, 95% CI 3.9–15, P < 0.001).
MDRTB. Fifty-one (18%) of 287 patients had MDRTB,
and 31/51 (61%) of them were HIV-positive. Of all 72 HIV-
positive patients, 31 (43%) had MDRTB. In addition to the
drug-susceptibility data from our university laboratory, sus-
ceptibilities were also available from the Ministry of Health
clinical laboratory for 32 (50%) of patients at the infectious
diseases unit, and there was complete concordance in all ex-
cept 3 cases. Twelve (30%) of the 40 MDRTB patients be-
came culture-negative on treatment, despite 6 of them receiv-
ing only standard first-line tuberculosis therapy and 8 of them
being HIV-negative.
Risk factors for MDRTB. MDRTB was associated in mul-
tiple regression (all P  0.01) with previous tuberculosis
treatment (HR  2.8, 95% CI  1.3–5.9), previous tubercu-
losis preventive therapy (HR  7.9, 95% CI  2.3–27), and
current tuberculosis diagnosis made at the infectious diseases
unit (HR  4.9, 95% CI  2.4–10). To evaluate the inde-
pendent effect of recruitment center, data were also analyzed
separately according to recruitment clinic. The general hos-
pital had 21 (9%) of the MDRTB patients, but none of their
recorded characteristics was significantly associated with drug
resistance (all P > 0.1). At the infectious diseases unit, where
all patients were HIV-positive, 30 (47%) of them had
MDRTB. Multiple regression analysis revealed that MDRTB
was associated with previous tuberculosis preventive therapy
(HR  16, 95% CI  2.8–85, P  0.002) and recent hospi-
talization (HR  6.8, 95% CI  1.9–24, P  0.003).
DISCUSSION
This study demonstrates the profound impact of HIV in-
fection and multi-drug resistance on survival and infectious-
ness in tuberculosis patients. Survival throughout treatment
was almost universal in HIV-negative individuals, irrespective
of drug susceptibilities. However, most HIV-positive patients
co-infected with tuberculosis died during therapy, and most of
those co-infected with MDRTB died in the first 2 months of
treatment. Conventional drug-susceptibility testing used
throughout the less-developed world would have identified
MDRTB before death in only a minority of these cases,
whereas inexpensive, recently reported techniques could have
more rapidly provided this information and allowed appro-
priate therapy to be instituted.7,12,15 Most patients with
MDRTB remained infectious throughout therapy, which is a
concern because facilities for respiratory isolation of inpa-
tients or outpatients are limited in less-developed countries.
TABLE 2
Risk factor analysis for mortality
Feature
Kaplan-Meier Cox regression
Log-rank test P value Hazard ratio 95% CI P value
HIV seropositivity 130 < 0.001 99 13–730 < 0.001
MDRTB at time of diagnosis 65 < 0.001 2.5 1.4–4.5 0.002
Previous TB treatment 16 0.001 2.1 1.1–3.7 0.02
Known exposure to TB at home/work 4.5 0.03 0.5 0.3–1.0 0.05
Diagnosed in the infectious diseases unit 118 < 0.001 ns
Previous TB preventive therapy 29 < 0.001 ns
Hospitalization in last 2 years 26 < 0.001 ns
Male sex 4.9 0.03 ns
BCG scar(s) 0.14 ns – – –
Age in years – – ns
Note: Relative risk of mortality associated with each patient’s initial clinical characteristics is shown for Kaplan-Meier survival analysis and in a Cox regression model, together with 95%
confidence intervals.
Abbreviations: HIV, human immunodeficiency virus; MDRTB, multi-drug resistant tuberculosis; TB, tuberculosis; BCG, Bacillus Calmette-Guerin; SD, standard deviation; ID, infectious
diseases; CI, confidence interval; ns, no significant difference; “–” signifies that analysis of that variable was not appropriate (see methods).
FIGURE 1. Kaplan-Meier analysis of mortality following com-
mencement of tuberculosis therapy. The study population is divided
according to HIV serology (HIV negative or positive) and tubercu-
losis drug resistance at the time of enrollment (MDR, strains resistant
to isoniazid and rifampicin; DS, drug-susceptible, non-MDR strains);
n, number of patients alive at the end of follow-up/the number
of patients recruited to that diagnostic group; ●, patient whose follow-
up ended at that time because of completion of or default from fol-
low-up.
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Mortality. Two-thirds of the HIV-positive tuberculosis pa-
tients died during follow-up, which is a rate that is greater
than in most reports, even after allowing for differences in
follow-up3,16 and MDRTB.17,18 However, there are reports of
similarly high mortality,19 and Peruvian mortality during
treatment of first episodes of AIDS-associated tuberculosis
approached this level, falling from 63% to 39% from 1996 to
1999.20,21 The cause of death in these patients could not be
confirmed to be AIDS-associated tuberculosis in these pub-
lished studies nor in the present research because autopsies
were not performed; it is therefore possible that other AIDS-
related diseases contributed to these high mortality rates. De-
layed diagnosis,22,23 minimal access to anti-retroviral drugs,24
and co-existent infections17 may also have contributed. How-
ever, the median survival time of these patients at the infec-
tious diseases unit was 61 months from the time of HIV di-
agnosis but < 6 months from the diagnosis of tuberculosis
co-infection, indicating the major risk associated with a tu-
berculosis diagnosis in HIV-positive people in this setting.
In contrast, there was minimal mortality in HIV-negative
patients, including those with MDRTB, reflecting the re-
nowned Peruvian tuberculosis program. For > 10 years, this
program has provided > 99% of the Peruvian population all
five components of the World Health Organization DOTS
policy: government commitment to sustained TB control; bac-
teriological diagnosis; standardized short-course chemo-
therapy regimens under close supervision; a proper drug sup-
ply system; and recording/reporting of cases and results.2,5,18
It is noteworthy that most of the HIV-positive and HIV-
negative participants were outpatients at the time that tuber-
culosis was diagnosed, and only a minority had been hospi-
talized in the past 2 years (Table 1), implying that tuberculosis
was not acquired during hospitalization for other terminal
diseases.
Infectiousness. Although HIV status was the principle de-
terminant of survival, MDRTB was the main determinant of
infectiousness. Of those with MDRTB, approximately half of
the HIV-negative and almost all of the HIV-positive patients
remained sputum smear- and/or culture-positive throughout
treatment. Follow-up sputum culture data are rarely available
in less-developed countries, although most tuberculosis oc-
curs there. It is significant that sputum cultures almost exactly
mirrored sputum smears, implying that positive sputum
smears did not generally result from mycobacteria that had
been killed by treatment. When sensitive broth culture is
used, sputum smear-positivity usually indicates culture-
positivity.25 This implies that sputum smears are reliable in-
dicators of the duration of infectiousness.
HIV co-infection did not significantly influence the dura-
tion of infectiousness during treatment.14 This contrasts with
countries with very little MDRTB, where prolonged culture-
positivity is infrequent.4 Peru has high tuberculosis and
MDRTB prevalences.2,7,26–30 In this setting, conventional
treatment of MDRTB for immunocompetent people was as-
sociated with good survival but frequently maintained infec-
tiousness. Although we did not study secondary tuberculosis
in contacts or radiographic data to assess disease severity, it is
well established that sputum smear and culture positivity are
risk factors for tuberculosis and MDRTB dissemination.6 As
a result of this research, the infectious diseases unit is now
providing same-day sputum tuberculosis microscopy for HIV-
positive patients with respiratory symptoms, rapid initiation
of therapy after diagnosis, respiratory isolation of smear-
positive patients, and increased use of personal respirator
masks.
MDRTB rates. The MDRTB rates found for HIV co-
infected patients in the present study were similar to recent
Lima-based research,30 but MDRTB rates were higher than
nationally,20 even in the general clinic where we recruited
unselected, predominantly HIV-negative residents. However,
in much of the less-developed world, including Peru, drug-
susceptibility testing is restricted to high-risk groups, includ-
ing HIV co-infection and those who have failed several
months of first-line tuberculosis therapy. Our results imply
FIGURE 2. Kaplan-Meier analysis of infectiousness following commencement of TB therapy. Infectiousness is assessed as sputum smear
positivity in a and as sputum culture positivity in b. The study population is divided according to HIV serology (HIV negative or positive) and
tuberculosis drug resistance (“MDR” refers to strains resistant to isoniazid and rifampicin; “DS” refers to all other strains) at the time of
enrollment; n, number of patients known to be sputum-smear- or culture-negative by the end of follow-up/the number of patients recruited to that
diagnostic group; “●” signifies end of follow-up because of completion of or default from the study.
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that many patients with MDRTB and unrecognized HIV co-
infection die before they meet these criteria, so MDRTB may
be under-diagnosed.
In this study, patients with initially unrecognized MDRTB
completed a trial of first-line therapy despite MDRTB being
diagnosed during first-line therapy. These MDRTB results
were provided routinely by the Ministry of Health for all new
tuberculosis diagnoses in HIV-positive and some other pa-
tients and by our research for all patients. This initial trial of
first-line therapy is explained by the observations that (1)
first-line therapy includes at least two drugs to which most
MDRTB is susceptible and consequently much MDRTB ap-
pears to be cured by first-line therapy5,31–33; (2) second-line
MDRTB therapy is expensive and toxic34; (3) failure of first-
line therapy reliably predicts MDRTB35; and (4) conven-
tional drug-susceptibility testing identifies MDRTB too late
to influence the first months of therapy.10 Hence, the patients
with MDRTB in this study first had to survive failing 6–9
months of first-line therapy before receiving specific MDRTB
therapy. This was associated with mortality and prolonged
MDRTB infectiousness, in contrast to the excellent prog-
noses for MDRTB treated with specific therapy in Peru.34,36
The present results imply that rapid, early MDRTB testing is
a priority and that, when MDRTB is diagnosed, appropriate
therapy should be instituted urgently, without awaiting
completion of a trial of second-line therapy. Second-line an-
tibiotics for MDRTB and highly active anti-retroviral therapy
have both become much more widely available in Peru,34 and
rapid MDRTB tests,15 including the MODS assay that we
used,11,12 have become approved components of the Peruvian
National Tuberculosis Control policy.37
Recently, a community-based MDRTB treatment program
achieved a cure rate of 73% among 75 patients.34 Although
this represents a breakthrough in MDRTB care, antibiotic
costs were US dollars (USD) 15,681 per patient, a price be-
yond the reach of most programs. Also, this selected patient
group had survived a median of 4 years of intermittent
therapy before this therapy, demonstrating chronic disease.
Similarly, a standardized regimen of MDRTB treatment ad-
ministered by the Peruvian tuberculosis program cured 48%
of MDRTB patients.36 Together, these results indicate poten-
tial to prevent mortality where resources exist for rapid test-
ing and specific MDRTB therapy.
MDRTB is associated with previous tuberculosis treat-
ment,4,30 and we also found an association with previous iso-
niazid preventive therapy, unlike other studies.30,38–40 This
could be explained by a covariate, such as duration of AIDS,
increasing the likelihood of both preventive therapy and nos-
ocomial MDRTB exposure. Alternatively, isoniazid preven-
tive monotherapy could have increased the risk of subsequent
isoniazid and rifampicin resistance. A recent study of the risk
factors for MDRTB for HIV-positive and negative patients in
Lima30 and our present study both demonstrated associations
between MDRTB and past tuberculosis treatment, hospital-
izations, and care in centers for people with HIV. This recent
case-control study was not designed to test for HIV effects on
MDRTB risk, and therefore it is important to note that in the
present study HIV co-infection was not independently asso-
ciated with MDRTB risk.
Reliability. Studies of this kind can be confounded by labo-
ratory cross-contamination,41 although care was taken to pre-
vent this, including using closed culture wells.11 Evidence that
sputum results diagnosed disease rather than contamination
was provided by (1) association with mortality; (2) agreement
between drug-susceptibility testing in separately collected
samples processed in different laboratories; and (3) concor-
dance between independent microscopy and culture in our
laboratory.
Implications. Most patients with MDRTB remained infec-
tious throughout suboptimal therapy designed for drug-
susceptible tuberculosis. Greater use of drug-susceptibility
testing would allow appropriate therapy, when available, to
improve prognosis34,42 and potentially reduce MDRTB trans-
mission. Early MDRTB diagnosis may also prevent therapy
with inappropriate regimes from causing MDRTB strains to
develop additional resistance.43 Rapid culture and drug-
susceptibility testing would be required for appropriate
therapy to be instituted before most mortality occurred.
Techniques suitable for less-developed countries, such as the
MODS assay that we used, can provide drug susceptibilities in
5–14 days for USD 1–2 per sample,11,12 early and inexpensive
enough to potentially reduce mortality. Another priority is
improved infection control to reduce nosocomial transmis-
sion. Anti-retroviral drugs may considerably improve24 the
grave prognoses that we identified for patients with tubercu-
losis and HIV co-infection, and availability has recently in-
creased significantly in Peru.
CONCLUSION
This research demonstrated excellent prognoses for HIV-
negative individuals and rapid resolution of infectiousness for
patients with non-MDRTB. However, MDRTB patients had
prolonged infectiousness and, with HIV co-infection, more
than 50% mortality in the first 2 months of therapy. This
study therefore demonstrates the importance of early and
rapid drug-susceptibility testing, improved infection control
measures, and early anti-retroviral therapy so that patients
with MDRTB and HIV can receive appropriate therapy early
enough to reduce their mortality and potential to infect oth-
ers.
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